Intellia Therapeutics (NASDAQ: NTLA) is a clinical-stage genomic medicine company that develops CRISPR/Cas9-based therapies designed to permanently edit disease-causing genes inside the human body. The company does not generate product revenue; it funds operations through collaboration agreements, grants, and capital raises while advancing its pipeline toward potential regulatory approval and commercialization. The filing excerpts from the 10-K filed 2026-02-26 do not provide sufficient detail to characterize segment revenue, specific collaboration partners by name, headquarter address, founding year, current CEO tenure, or competitive positioning with named peers. Based solely on the available filing content, Intellia operates as a pre-commercial biotechnology company with no disclosed product sales as of the fiscal year ended 2025, spending its capital on research, development, and clinical trials for in vivo and ex vivo gene-editing programs.

Source: SEC 10-K, filed 2026-02-26

Industry: In Vitro & In Vivo Diagnostic Substances Peers: Cerevel Therapeutics Holdings, Inc. Blueprint Medicines Corp ChemoCentryx, Inc. Cytokinetics Inc Exelixis Inc Global Blood Therapeutics, Inc. Natera Inc Mirati Therapeutics, Inc.